LYMPHOMAS

Based on data from a phase 1/2 study, a biologics license application has been accepted for glofitimab and the product has been granted priority review to for relapsed/refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.

In the diffuse large B-cell lymphoma and follicular lymphoma cohorts of the ELM-1 and ELM-2 trials, odronextamab led to high overall response rates.

Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.

Phase 2 study results show the durability of response associated with mosunetuzumab in patients with relapsed or refractory follicular lymphoma.

The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel.

In the phase 3 TRANSFORM study, lisocabtagene maraleucel bested standard of care as treatment of patients with high-risk relapsed/refractory large B-cell lymphoma.

The use of iberdomide alone or with anti-CD20 antibodies show efficacy in patients with relapsed or refractory lymphoma.

MAGNOLIA study results demonstrated that zanubrutinib maintained response in patients with relapsed/refractory marginal zone lymphoma.

Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

In an interview with Targeted Oncology, David J. Straus, MD, discussed the newest data of the ECHELON-1 trial which he presented at the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.

Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.

The FDA will conduct a regular review of the application submitted for approval of I/ONTAK in patients with persistent or recurrent cutaneous T-cell lymphoma.

The allogeneic CAR T-cell therapy CB-010 received regenerative medicine advanced therapy and Fast Track designations for the treatment of patients with B-cell non-Hodgkin lymphoma.

In an interview with Targeted Oncology, Chelsea C. Pinnix discussed the results of a phase 2 study and how these promising results will shift the treatment paradigm of patients with orbital indolent B-cell lymphoma.

In an interview with Targeted Oncology, Michael T. Tees, MD, discussed the donor-derived CAR T-cell product, ALLO-501A, and research supporting the agent.

Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.

Based on results from the phase 3 AHOD1331 trial, the FDA has approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients with high-risk classical Hodgkin lymphoma.

The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.

Nitin Jain, MD, discusses clinical trials investigating allogeneic chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Positive efficacy and safety results from the phase 3 EPCORE™ NHL-1 trial have lead to an FDA application for approval of epcoritamab to treat relapsed or refractory large B-cell lymphoma.

At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.

During a case-based rountable event, Jasmine Zain, MD of City of Hope, discussed the case of a 79-year-old patients with relapsed or refractory diffuse large B-cell lymphoma.